8PHI

Crystal structure of prefusion-stabilized RSV F Variant DS-Cav1 in complex with Lonafarnib

Summary for 8PHI

• Entry DOI: 10.2210/pdb8phi/pdb
• Descriptor: Fusion glycoprotein F0, 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE, SULFATE ION, ... (6 entities in total)
• Functional Keywords: rsv f glycoprotein, inhibitor, viral protein
• Biological source: Human respiratory syncytial virus A2
• Total number of polymer chains: 1
• Total formula weight: 62596.40

Authors

Rajak, M.,Krey, T. (deposition date: 2023-06-19, release date: 2024-02-21)

• Primary citation: Sake, S.M.,Zhang, X.,Rajak, M.K.,Urbanek-Quaing, M.,Carpentier, A.,Gunesch, A.P.,Grethe, C.,Matthaei, A.,Ruckert, J.,Galloux, M.,Larcher, T.,Le Goffic, R.,Hontonnou, F.,Chatterjee, A.K.,Johnson, K.,Morwood, K.,Rox, K.,Elgaher, W.A.M.,Huang, J.,Wetzke, M.,Hansen, G.,Fischer, N.,Eleouet, J.F.,Rameix-Welti, M.A.,Hirsch, A.K.H.,Herold, E.,Empting, M.,Lauber, C.,Schulz, T.F.,Krey, T.,Haid, S.,Pietschmann, T.; Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.; Nat Commun, 15:1173-1173, 2024; PubMed: 38332002; DOI: 10.1038/s41467-024-45241-y

Experimental method

X-RAY DIFFRACTION (2.289 Å)